BRTX
NASDAQ · Biotechnology
Biorestorative Therapies Inc
$1.04
+0.02 (+1.96%)
Open$1.04
Previous Close$1.02
Day High$1.13
Day Low$1.01
52W High$26.91
52W Low$20.27
Volume—
Avg Volume315.0K
Market Cap9.23M
P/E Ratio—
EPS$-1.84
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,416.3% upside
Current
$1.04
$1.04
Target
$26.17
$26.17
$18.72
$26.17 avg
$39.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.95M | 1.76M | 1.61M |
| Net Income | 368.5K | 288.6K | 237.9K |
| Profit Margin | 18.9% | 16.4% | 14.8% |
| EBITDA | 506.9K | 503.0K | 417.7K |
| Free Cash Flow | 427.1K | 335.8K | 390.7K |
| Rev Growth | +23.8% | +14.5% | +14.3% |
| Debt/Equity | 0.56 | 0.52 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |